Limb girdle muscular dystrophies: Update on genetic diagnosis and therapeutic approaches

Current Opinion in Neurology

Volumn 24, Issue 5, 2011, Pages 429-436

  Nigro, Vincenzo ^a,b   Aurino, Stefania ^a,b   Piluso, Giulio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

Author keywords

Diagnosis; genetic testing; limb girdle muscular dystrophy; therapy

Indexed keywords

ALPHA SARCOGLYCAN; BETA SARCOGLYCAN; CALPAIN 3; CONNECTIN; DEFLAZACORT; DELTA SARCOGLYCAN; DYSFERLIN; DYSTROGLYCAN; FUKUTIN; GAMMA SARCOGLYCAN; MUSCLE PROTEIN; PLACEBO; TELETHONIN; UNCLASSIFIED DRUG;

DNA DETERMINATION; GENE MUTATION; GENE SEQUENCE; GENE THERAPY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; LIMB GIRDLE MUSCULAR DYSTROPHY 1A; LIMB GIRDLE MUSCULAR DYSTROPHY 1B; LIMB GIRDLE MUSCULAR DYSTROPHY 1C; LIMB GIRDLE MUSCULAR DYSTROPHY 1D; LIMB GIRDLE MUSCULAR DYSTROPHY 1E; LIMB GIRDLE MUSCULAR DYSTROPHY 1F; LIMB GIRDLE MUSCULAR DYSTROPHY 1G; LIMB GIRDLE MUSCULAR DYSTROPHY 1H; LIMB GIRDLE MUSCULAR DYSTROPHY 2A; LIMB GIRDLE MUSCULAR DYSTROPHY 2B; LIMB GIRDLE MUSCULAR DYSTROPHY 2C; LIMB GIRDLE MUSCULAR DYSTROPHY 2D; LIMB GIRDLE MUSCULAR DYSTROPHY 2E; LIMB GIRDLE MUSCULAR DYSTROPHY 2F; LIMB GIRDLE MUSCULAR DYSTROPHY 2G; LIMB GIRDLE MUSCULAR DYSTROPHY 2H; LIMB GIRDLE MUSCULAR DYSTROPHY 2I; LIMB GIRDLE MUSCULAR DYSTROPHY 2J; LIMB GIRDLE MUSCULAR DYSTROPHY 2K; LIMB GIRDLE MUSCULAR DYSTROPHY 2L; LIMB GIRDLE MUSCULAR DYSTROPHY 2M; LIMB GIRDLE MUSCULAR DYSTROPHY 2N; LIMB GIRDLE MUSCULAR DYSTROPHY 2O; LIMB GIRDLE MUSCULAR DYSTROPHY 2P; NEXT GENERATION SEQUENCING; PHENOTYPE; REVIEW;

ANIMALS; BIOPSY; DISEASE MODELS, ANIMAL; HUMANS; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES, LIMB-GIRDLE;

EID: 80052477741     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32834aa38d     Document Type: Review

References (98)

1. Fanin M, Nascimbeni AC, Aurino S, et al. Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Neurology 2009; 72:1432-1435.
2. Bushby K. Diagnosis and management of the limb girdle muscular dystrophies. Pract Neurol 2009; 9:314-323.
3. Wattjes MP, Kley RA, Fischer D. Neuromuscular imaging in inherited muscle diseases. Eur Radiol 2010; 20:2447-2460.
4. Nigro V. Molecular bases of autosomal recessive limb-girdle muscular dystrophies. Acta Myol 2003; 22:35-42. (Pubitemid 38005006)
5. Selcen D. Myofibrillar myopathies. Curr Opin Neurol 2010; 23:477-481.
6. Worman HJ, Fong LG, Muchir A, Young SG. Laminopathies and the long strange trip from basic cell biology to therapy. J Clin Invest 2009; 119:1825-1836.
7. Gazzerro E, Sotgia F, Bruno C, et al. Caveolinopathies: from the biology of caveolin-3 to human diseases. Eur J Hum Genet 2010; 18:137-145.
8. Sandell S, Huovinen S, Sarparanta J, et al. The enigma of 7q36 linked autosomal dominant limb girdle muscular dystrophy. J Neurol Neurosurg Psychiatry 2010; 81:834-839.
9. Bisceglia L, Zoccolella S, Torraco A, et al. A new locus on 3p23-p25 for an autosomal-dominant limb-girdle muscular dystrophy, LGMD1H. Eur J Hum Genet 2010; 18:636-641.
10. Guglieri M, Magri F, D'Angelo MG, et al. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat 2008; 29:258-266. (Pubitemid 351240598)
11. van der Kooi AJ, Frankhuizen WS, Barth PG, et al. Limb-girdle muscular dystrophy in the Netherlands: gene defect identified in half the families. Neurology 2007; 68:2125-2128. (Pubitemid 46912131)
12. Moore SA, Shilling CJ, Westra S, et al. Limb-girdle muscular dystrophy in the United States. J Neuropathol Exp Neurol 2006; 65:995-1003. (Pubitemid 44521800)
13. Piluso G, Politano L, Aurino S, et al. Extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2A phenotypes. J Med Genet 2005; 42:686-693. (Pubitemid 41306058)
14. Pathak P, SharmaMC, Sarkar C, et al. Limb girdle muscular dystrophy type 2A in India: a study based on semi-quantitative protein analysis, with clinical and histopathological correlation. Neurol India 2010; 58:549-554.
15. Lo HP, Cooper ST, Evesson FJ, et al. Limb-girdle muscular dystrophy: diagnostic evaluation, frequency and clues to pathogenesis. Neuromuscul Disord 2008; 18:34-44. (Pubitemid 351181397)
16. Sayers EW, Barrett T, Benson DA, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2011; 39:D38-51.
17. Garnham CP, Hanna RA, Chou JS, et al. Limb-girdle muscular dystrophy type 2A can result from accelerated autoproteolytic inactivation of calpain 3. Biochemistry 2009; 48:3457-3467.
18. Ojima K, Kawabata Y, Nakao H, et al. Dynamic distribution of muscle-specific calpain in mice has a key role in physical-stress adaptation and is impaired in muscular dystrophy. J Clin Invest 2010; 120:2672-2683.
19. de Morree A, Lutje Hulsik D, Impagliazzo A, et al. Calpain 3 is a rapid-action, unidirectional proteolytic switch central to muscle remodeling. PLoS One 2010; 5:e11940.
20. Mercuri E, Bushby K, Ricci E, et al. Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures. Neuromuscul Disord 2005; 15:164-171. (Pubitemid 40202743)
21. de Paula F, Vainzof M, Passos-Bueno MR, et al. Clinical variability in calpainopathy: what makes the difference? Eur J Hum Genet 2002; 10:825-832. (Pubitemid 36054564)
22. Krahn M, Lopez de Munain A, Streichenberger N, et al. CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol 2006; 59:905-911. (Pubitemid 43830922)
23. Krahn M, Goicoechea M, Hanisch F, et al. Eosinophilic infiltration related to CAPN3 mutations: a pathophysiological component of primary calpainopathy? Clin Genet 2010 [Epub ahead of print].
24. Baumeister SK, Todorovic S, Milic-Rasic V, et al. Eosinophilic myositis as presenting symptom in gamma-sarcoglycanopathy. Neuromuscul Disord 2009; 19:167-171.
25. Anderson LV, Davison K, Moss JA, et al. Characterization of monoclonal antibodies to calpain 3 and protein expression in muscle from patients with limb-girdle muscular dystrophy type 2A. Am J Pathol 1998; 153:1169-1179. (Pubitemid 28465840)
26. Fanin M, Nascimbeni AC, Tasca E, Angelini C. How to tackle the diagnosis of limb-girdle muscular dystrophy 2A. Eur J Hum Genet 2009; 17:598-603.
27. Anderson LV, Harrison RM, Pogue R, et al. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord 2000; 10:553-559.
28. Haravuori H, Vihola A, Straub V, et al. Secondary calpain3 deficiency in 2qlinked muscular dystrophy: titin is the candidate gene. Neurology 2001; 56:869-877. (Pubitemid 32290803)
29. Charlton R, Henderson M, Richards J, et al. Immunohistochemical analysis of calpain 3: advantages and limitations in diagnosing LGMD2A. Neuromuscul Disord 2009; 19:449-457.
30. Nascimbeni AC, Fanin M, Tasca E, Angelini C. Transcriptional and translational effects of intronic CAPN3 gene mutations. Hum Mutat 2010; 31:E1658-E1669.
31. Krahn M, Pecheux C, Chapon F, et al. Transcriptional explorations of CAPN3 identify novel splicing mutations, a large-sized genomic deletion and evidence for messenger RNA decay. Clin Genet 2007; 72:582-592. (Pubitemid 350131067)
32. Duno M, Sveen ML, Schwartz M, Vissing J. cDNA analyses of CAPN3 enhance mutation detection and reveal a low prevalence of LGMD2A patients in Denmark. Eur J Hum Genet 2008; 16:935-940.
33. Nalini A, Gayathri N. Dysferlinopathy: a clinical and histopathological study of patients from India. Neurol India 2008; 56:379-385; discussion 386-377.
34. Bansal D, Miyake K, Vogel SS, et al. Defective membrane repair in dysferlindeficient muscular dystrophy. Nature 2003; 423:168-172. (Pubitemid 36569539)
35. Rosales XQ, Gastier-Foster JM, Lewis S, et al. Novel diagnostic features of dysferlinopathies. Muscle Nerve 2010; 42:14-21.
36. Klinge L, Dean AF, Kress W, et al. Late onset in dysferlinopathy widens the clinical spectrum. Neuromuscul Disord 2008; 18:288-290.
37. Nguyen K, Bassez G, Krahn M, et al. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 2007; 64:1176-1182. (Pubitemid 47258078)
38. Weiler T, Bashir R, Anderson LV, et al. Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). Hum Mol Genet 1999; 8:871-877. (Pubitemid 29189055)
39. Paradas C, Llauger J, Diaz-Manera J, et al. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology 2010; 75:316-323.
40. Fischer D, Walter MC, Kesper K, et al. Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs. J Neurol 2005; 252:538-547. (Pubitemid 40768169)
41. Klinge L, Aboumousa A, Eagle M, et al. New aspects on patients affected by dysferlin deficient muscular dystrophy. J Neurol Neurosurg Psychiatry 2010; 81:946-953.
42. Chiu YH, Hornsey MA, Klinge L, et al. Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy. Hum Mol Genet 2009; 18:1976-1989.
43. Cacciottolo M, Numitone G, Aurino S, et al. Muscular dystrophy with marked dysferlin deficiency is consistently caused by primary dysferlin gene mutations. Eur J Hum Genet 2011 [Epub ahead of print]. A recent study demonstrating that 100% of LGMD2B mutations can be identified by a combination of molecular methods.
44. De Luna N, Freixas A, Gallano P, et al. Dysferlin expression in monocytes: a source of mRNA for mutation analysis. Neuromuscul Disord 2007; 17:69-76. (Pubitemid 46186004)
45. Sandona D, Betto R. Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects. Expert Rev Mol Med 2009; 11:e28.
46. Vainzof M, Passos-Bueno MR, Pavanello RC, et al. Sarcoglycanopathies are responsible for 68% of severe autosomal recessive limb-girdle muscular dystrophy in the Brazilian population. J Neurol Sci 1999; 164:44-49. (Pubitemid 29256072)
47. Khadilkar SV, Singh RK, Hegde M, et al. Spectrum of mutations in sarcoglycan genes in the Mumbai region of western India: high prevalence of 525del T. Neurol India 2009; 57:406-410.
48. Piccolo F, Jeanpierre M, Leturcq F, et al. A founder mutation in the gammasarcoglycan gene of gypsies possibly predating their migration out of India. Hum Mol Genet 1996; 5:2019-2022. (Pubitemid 26413648)
49. McNally EM, Passos-Bueno MR, Bonnemann CG, et al. Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation. Am J Hum Genet 1996; 59:1040-1047. (Pubitemid 26346344)
50. Fanin M, Melacini P, Boito C, et al. LGMD2E patients risk developing dilated cardiomyopathy. Neuromuscul Disord 2003; 13:303-309. (Pubitemid 36962698)
51. Politano L, Nigro V, Passamano L, et al. Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromuscul Disord 2001; 11:178-185. (Pubitemid 32197522)
52. Nigro V, Okazaki Y, Belsito A, et al. Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet 1997; 6:601-607. (Pubitemid 27142112)
53. Cheng L, Guo XF, Yang XY, et al. Delta-sarcoglycan is necessary for early heart and muscle development in zebrafish. Biochem Biophys Res Commun 2006; 344:1290-1299.
54. Wildforster V, Dekomien G. Detecting copy number variations in autosomal recessive limb-girdle muscular dystrophies using a multiplex ligationdependent probe amplification (MLPA) assay. Mol Cell Probes 2009; 23:55-59.
55. Nowak KJ, Walsh P, Jacob RL, et al. Severe gamma-sarcoglycanopathy caused by a novel missense mutation and a large deletion. Neuromuscul Disord 2000; 10:100-107. (Pubitemid 30050621)
56. Ferreiro A, Mezmezian M, Olive M, et al. Telethonin-deficiency initially presenting as a congenital muscular dystrophy. Neuromuscul Disord 2011; 21:433-438.
57. Hayashi T, Arimura T, Itoh-Satoh M, et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol 2004; 44:2192-2201. (Pubitemid 39576040)
58. Rampersaud E, Kinnamon DD, Hamilton K, et al. Common susceptibility variants examined for association with dilated cardiomyopathy. Ann Hum Genet 2010; 74:110-116.
59. McNab FW, Rajsbaum R, Stoye JP, O'Garra A. Tripartite-motif proteins and innate immune regulation. Curr Opin Immunol 2011; 23:46-56.
60. Frosk P, Weiler T, Nylen E, et al. Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am J Hum Genet 2002; 70:663-672. (Pubitemid 34177921)
61. Schoser BG, Frosk P, Engel AG, et al. Commonality of TRIM32 mutation in causing sarcotubular myopathy and LGMD2H. Ann Neurol 2005; 57:591-595. (Pubitemid 40471176)
62. Saccone V, Palmieri M, Passamano L, et al. Mutations that impair interaction properties of TRIM32 associated with limb-girdle muscular dystrophy 2H. Hum Mutat 2008; 29:240-247. (Pubitemid 351240596)
63. Cossee M, Lagier-Tourenne C, Seguela C, et al. Use of SNP array analysis to identify a novel TRIM32 mutation in limb-girdle muscular dystrophy type 2H. Neuromuscul Disord 2009; 19:255-260.
64. Borg K, Stucka R, Locke M, et al. Intragenic deletion of TRIM32 in compound heterozygotes with sarcotubular myopathy/LGMD2H. Hum Mutat 2009; 30:E831-E844.
65. Brockington M, Yuva Y, Prandini P, et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet 2001; 10:2851-2859. (Pubitemid 34030916)
66. Godfrey C, Foley AR, Clement E, Muntoni F. Dystroglycanopathies: coming into focus. Curr Opin Genet Dev 2011; 21:278-285.
67. Van Reeuwijk J, Olderode-Berends MJ, Van den Elzen C, et al. A homozygous FKRP start codon mutation is associated with Walker-Warburg syndrome, the severe end of the clinical spectrum. Clin Genet 2010; 78:275-281.
68. Stensland E, Lindal S, Jonsrud C, et al. Prevalence, mutation spectrum and phenotypic variability in Norwegian patients with Limb Girdle Muscular Dystrophy 2I. Neuromuscul Disord 2011; 21:41-46.
69. Poppe M, Cree L, Bourke J, et al. The phenotype of limb-girdle muscular dystrophy type 2I. Neurology 2003; 60:1246-1251. (Pubitemid 36460978)
70. Margeta M, Connolly AM, Winder TL, et al. Cardiac pathology exceeds skeletal muscle pathology in two cases of limb-girdle muscular dystrophy type 2I. Muscle Nerve 2009; 40:883-889.
71. Murakami T, Hayashi YK, Noguchi S, et al. Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. Ann Neurol 2006; 60:597-602. (Pubitemid 44871802)
72. Palmieri A, Manara R, Bello L, et al. Cognitive profile and MRI findings in limbgirdle muscular dystrophy 2I. J Neurol 2011; 258:1312-1320.
73. Mathews KD, Stephan CM, Laubenthal K, et al. Myoglobinuria and muscle pain are common in patients with limb-girdle muscular dystrophy 2I. Neurology 2011; 76:194-195.
74. Jimenez-Mallebrera C, Torelli S, Feng L, et al. A comparative study of alphadystroglycan glycosylation in dystroglycanopathies suggests that the hypoglycosylation of alpha-dystroglycan does not consistently correlate with clinical severity. Brain Pathol 2009; 19:596-611.
75. Hara Y, Balci-Hayta B, Yoshida-Moriguchi T, et al. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N Engl J Med 2011; 364:939-946.
76. Udd B, Vihola A, Sarparanta J, et al. Titinopathies and extension of the M-line mutation phenotype beyond distal myopathy and LGMD2J. Neurology 2005; 64:636-642. (Pubitemid 40261891)
77. Penisson-Besnier I, Hackman P, Suominen T, et al. Myopathies caused by homozygous titin mutations: limb-girdle muscular dystrophy 2J and variations of phenotype. J Neurol Neurosurg Psychiatry 2010; 81:1200-1202.
78. Charton K, Daniele N, Vihola A, et al. Removal of the calpain 3 protease reverses the myopathology in a mouse model for titinopathies. Hum Mol Genet 2010; 19:4608-4624.
79. Bolduc V, Marlow G, Boycott KM, et al. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet 2010; 86:213-221.
80. Hicks D, Sarkozy A, Muelas N, et al. A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain 2011; 134:171-182.
81. Mahjneh I, Jaiswal J, Lamminen A, et al. A new distal myopathy with mutation in anoctamin 5. Neuromuscul Disord 2010; 20:791-795.
82. Teer JK, Mullikin JC. Exome sequencing: the sweet spot before whole genomes. Hum Mol Genet 2010; 19:R145-R151. One of the best reviews on the next generation of sequencing applications.
83. Krahn M, Borges A, Navarro C, et al. Identification of different genomic deletions and one duplication in the dysferlin gene using multiplex ligationdependent probe amplification and genomic quantitative PCR. Genet Test Mol Biomarkers 2009; 13:439-442.
84. Papic L, Fischer D, Trajanoski S, et al. SNP-array based whole genome homozygosity mapping: a quick and powerful tool to achieve an accurate diagnosis in LGMD2 patients. Eur J Med Genet 2011; 54:214-219.
85. Boyden SE, Salih MA, Duncan AR, et al. Efficient identification of novel mutations in patients with limb girdle muscular dystrophy. Neurogenetics 2010; 11:449-455.
86. Santoro L, Nolano M, Faraso S, et al. Perioral skin biopsy to study skeletal muscle protein expression. Muscle Nerve 2010; 41:392-398.
87. Angelini C, Fanin M, Menegazzo E, et al. Homozygous alpha-sarcoglycan mutation in two siblings: one asymptomatic and one steroid-responsive mild limb-girdle muscular dystrophy patient. Muscle Nerve 1998; 21:769-775. (Pubitemid 28248682)
88. Darin N, Kroksmark AK, Ahlander AC, et al. Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I. Eur J Paediatr Neurol 2007; 11:353-357. (Pubitemid 47534996)
89. Godfrey C, Escolar D, Brockington M, et al. Fukutin gene mutations in steroidresponsive limb girdle muscular dystrophy. Ann Neurol 2006; 60:603-610. (Pubitemid 44871803)
90. Mendell JR, Rodino-Klapac LR, Rosales XQ, et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 2010; 68:629-638.
91. Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, et al. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol 2009; 66:290-297.
92. Vitiello C, Faraso S, Sorrentino NC, et al. Disease rescue and increased lifespan in a model of cardiomyopathy and muscular dystrophy by combined AAV treatments. PLoS One 2009; 4:e5051.
93. Barthelemy F, Wein N, Krahn M, et al. Translational research and therapeutic perspectives in dysferlinopathies. Mol Med 2011 [Epub ahead of print].
94. Wein N, Avril A, Bartoli M, et al. Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Hum Mutat 2010; 31:136-142.
95. Krahn M, Wein N, Bartoli M, et al. A naturally occurring human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dysferlinopathy. Sci Transl Med 2010; 2:50ra69.
96. Lostal W, Bartoli M, Bourg N, et al. Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet 2010; 19:1897-1907.
97. Han R, Frett EM, Levy JR, et al. Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. J Clin Invest 2010; 120:4366-4374.
98. Diaz-Manera J, Touvier T, Dellavalle A, et al. Partial dysferlin reconstitution by adult murine mesoangioblasts is sufficient for full functional recovery in a murine model of dysferlinopathy. Cell Death Dis 2010; 1:e61.